Drug Trial Radar · NCT04425018
MARGetuximab Or Trastuzumab (MARGOT)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
174
Actual
Start
Jul 13, 2020
Primary completion
Oct 24, 2024
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MacroGenics; Translational Breast Cancer Research Consortium
- First posted
- Jun 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)
Conditions
- Breast Cancer
- Stage II Breast Cancer
- Stage III Breast Cancer
- HER2-positive Breast Cancer
Interventions
PaclitaxelDrug
Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
PertuzumabDrug
Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
MargetuximabDrug
Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
TrastuzumabDrug
Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic Complete Response (pCR)Time frame: 12 weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Georgetown University Medical Center
Washington D.C., District of Columbia
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Dana-Farber Brigham Cancer Center - Foxborough
Foxborough, Massachusetts
Dana-Farber at Milford
Milford, Massachusetts
Dana-Farber at South Shore Hospital
Weymouth, Massachusetts
Montefiore Medical Center
The Bronx, New York
UPMC Hillman Cancer Center - Arnold Palmer at Mountain View
Greensburg, Pennsylvania
UPMC Hillman Cancer Center - Arnold Palmer at Norwin
Irwin, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Baylor College of Medicine Medical Center
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
University of Washington Fred Hutchinson Cancer Care
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.